-
1
-
-
84865552100
-
Immuno-oncology: Understanding the function and dysfunction of the immune system in cancer
-
Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann. Oncol. 23, viii6-viii9 (2012).
-
(2012)
Ann. Oncol
, vol.23
, pp. 86-89
-
-
Finn, O.J.1
-
2
-
-
79952284127
-
Hallmarks of cancer: The next generation
-
Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
-
(2011)
Cell
, vol.144
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.2
-
3
-
-
79953151458
-
Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion
-
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570 (2011).
-
(2011)
Science
, vol.331
, pp. 1565-1570
-
-
Schreiber, R.D.1
Old, L.J.2
Smyth, M.J.3
-
4
-
-
84965092294
-
Cancer: A biological approach. I. The processes of control
-
Burnet M. Cancer: a biological approach. I. The processes of control. Br. Med. J. 1, 779-786 (1957).
-
(1957)
Br. Med. J
, vol.1
, pp. 779-786
-
-
Burnet, M.1
-
5
-
-
34547657483
-
Incidence of malignancies in heart and/or lung transplant recipients: A single-institution experience
-
Roithmaier S, Haydon AM, Loi S et al. Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience. J. Heart Lung Transpl. 26, 845-849 (2007).
-
(2007)
J. Heart Lung Transpl
, vol.26
, pp. 845-849
-
-
Roithmaier, S.1
Haydon, A.M.2
Loi, S.3
-
6
-
-
70349256093
-
Cancer incidence and risk factors after solid organ transplantation
-
Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int. J. Cancer 125, 1747-1754 (2009).
-
(2009)
Int. J. Cancer
, vol.125
, pp. 1747-1754
-
-
Vajdic, C.M.1
Van Leeuwen, M.T.2
-
7
-
-
0027478361
-
Identification of human cancers deficient in antigen processing
-
Restifo NP, Esquivel F, Kawakami Y et al. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177, 265-272 (1993).
-
(1993)
J. Exp. Med
, vol.177
, pp. 265-272
-
-
Restifo, N.P.1
Esquivel, F.2
Kawakami, Y.3
-
8
-
-
84858784892
-
Targeting natural killer cells and natural killer T cells in cancer
-
Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat. Rev. Immunol. 12, 239-252 (2012).
-
(2012)
Nat. Rev. Immunol
, vol.12
, pp. 239-252
-
-
Vivier, E.1
Ugolini, S.2
Blaise, D.3
Chabannon, C.4
Brossay, L.5
-
9
-
-
0022616253
-
Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy
-
Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319, 675-678 (1986).
-
(1986)
Nature
, vol.319
, pp. 675-678
-
-
Karre, K.1
Ljunggren, H.G.2
Piontek, G.3
Kiessling, R.4
-
10
-
-
70449193189
-
Immunity to methylcholanthrene-induced sarcomas
-
Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J. Natl Cancer Inst. 18, 769-778 (1957).
-
(1957)
J. Natl Cancer Inst
, vol.18
, pp. 769-778
-
-
Prehn, R.T.1
Main, J.M.2
-
11
-
-
0026322151
-
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
-
van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647 (1991).
-
(1991)
Science
, vol.254
, pp. 1643-1647
-
-
Van Der Bruggen, P.1
Traversari, C.2
Chomez, P.3
-
12
-
-
27244448135
-
Tumor antigens and tumor antigen discovery
-
Graziano DF, Finn OJ. Tumor antigens and tumor antigen discovery. Cancer Treat. Res. 123, 89-111 (2005).
-
(2005)
Cancer Treat. Res
, vol.123
, pp. 89-111
-
-
Graziano, D.F.1
Finn, O.J.2
-
14
-
-
0242266480
-
Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression
-
Houston A, Bennett MW, O'Sullivan GC, Shanahan F, O'Connell J. Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression. Br. J. Cancer 89, 1345-1351 (2003).
-
(2003)
Br. J. Cancer
, vol.89
, pp. 1345-1351
-
-
Houston, A.1
Bennett, M.W.2
O'Sullivan, G.C.3
Shanahan, F.4
O'Connell, J.5
-
15
-
-
35948933046
-
Transforming growth factor-b and the immune response to malignant disease
-
Teicher BA. Transforming growth factor-b and the immune response to malignant disease. Clin. Cancer Res. 13, 6247-6251 (2007).
-
(2007)
Clin. Cancer Res
, vol.13
, pp. 6247-6251
-
-
Teicher, B.A.1
-
16
-
-
0142137237
-
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
-
Uyttenhove C, Pilotte L, Theate I et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269-1274 (2003).
-
(2003)
Nat. Med
, vol.9
, pp. 1269-1274
-
-
Uyttenhove, C.1
Pilotte, L.2
Theate, I.3
-
17
-
-
33847388907
-
Indoleamine 2,3-dioxygenase in immune suppression and cancer
-
Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr. Cancer Drug Targets 7, 31-40 (2007).
-
(2007)
Curr. Cancer Drug Targets
, vol.7
, pp. 31-40
-
-
Muller, A.J.1
Prendergast, G.C.2
-
18
-
-
0032555614
-
Prevention of allogeneic fetal rejection by tryptophan catabolism
-
Munn DH, Zhou M, Attwood JT et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281, 1191-1193 (1998).
-
(1998)
Science
, vol.281
, pp. 1191-1193
-
-
Munn, D.H.1
Zhou, M.2
Attwood, J.T.3
-
19
-
-
33645286546
-
Regulatory T cells, tumour immunity and immunotherapy
-
Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6, 295-307 (2006).
-
(2006)
Nat. Rev. Immunol
, vol.6
, pp. 295-307
-
-
Zou, W.1
-
20
-
-
0035874949
-
Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer
-
Woo EY, Chu CS, Goletz TJ et al. Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61, 4766-4772 (2001).
-
(2001)
Cancer Res
, vol.61
, pp. 4766-4772
-
-
Woo, E.Y.1
Chu, C.S.2
Goletz, T.J.3
-
21
-
-
34548804503
-
Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma
-
Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res. 67, 8865-8873 (2007).
-
(2007)
Cancer Res
, vol.67
, pp. 8865-8873
-
-
Bergmann, C.1
Strauss, L.2
Zeidler, R.3
Lang, S.4
Whiteside, T.L.5
-
22
-
-
34347375745
-
Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment
-
Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside T. Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. Cancer Immunol. Immunother. 56, 1429-1442 (2007).
-
(2007)
Cancer Immunol. Immunother
, vol.56
, pp. 1429-1442
-
-
Bergmann, C.1
Strauss, L.2
Zeidler, R.3
Lang, S.4
Whiteside, T.5
-
23
-
-
33645502885
-
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma
-
Fecci PE, Mitchell DA, Whitesides JF et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 66, 3294-3302 (2006).
-
(2006)
Cancer Res
, vol.66
, pp. 3294-3302
-
-
Fecci, P.E.1
Mitchell, D.A.2
Whitesides, J.F.3
-
25
-
-
0030240952
-
Immunotherapy for cancer
-
Old LJ. Immunotherapy for cancer. Sci. Am. 275, 136-143 (1996).
-
(1996)
Sci. Am
, vol.275
, pp. 136-143
-
-
Old, L.J.1
-
26
-
-
0026060863
-
The treatment of malignant tumors by repeated inoculations of erysipelas. with a report of ten original cases. 1893
-
Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin. Orthop. Relat. Res. 262, 3-11 (1991).
-
(1991)
Clin. Orthop. Relat. Res
, vol.262
, pp. 3-11
-
-
Coley, W.B.1
-
27
-
-
84865547199
-
Can immuno-oncology offer a truly pan-Tumour approach to therapy?
-
Eggermont AMM. Can immuno-oncology offer a truly pan-Tumour approach to therapy? Annals Oncol. 23, viii53-viii57 (2012).
-
(2012)
Annals Oncol
, vol.23
, pp. 853-857
-
-
Amm, E.1
-
28
-
-
0025148037
-
The spontaneous regression of cancer. A review of cases from 1900 to 1987
-
Challis GB, Stam HJ. The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncol. 29, 545-550 (1990).
-
(1990)
Acta Oncol
, vol.29
, pp. 545-550
-
-
Challis, G.B.1
Stam, H.J.2
-
29
-
-
45549092607
-
Cancer immunology
-
Finn OJ. Cancer immunology. N. Engl. J. Med. 358, 2704-2715 (2008).
-
(2008)
N. Engl. J. Med
, vol.358
, pp. 2704-2715
-
-
Finn, O.J.1
-
30
-
-
0028266553
-
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
-
Rosenberg AA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271, 907-913 (1994).
-
(1994)
JAMA
, vol.271
, pp. 907-913
-
-
Rosenberg, A.A.1
Yang, J.C.2
Topalian, S.L.3
-
31
-
-
0035863468
-
Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma
-
Olsen E, Duvic M, Frankel A et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 19, 376-388 (2001).
-
(2001)
J. Clin. Oncol
, vol.19
, pp. 376-388
-
-
Olsen, E.1
Duvic, M.2
Frankel, A.3
-
33
-
-
34247504608
-
Depletion of CD4+CD25+ human regulatory T cells in vivo: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro
-
Mahnke K, Schönfeld K, Fondel S et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer 120, 2723-2733 (2007).
-
(2007)
Int. J. Cancer
, vol.120
, pp. 2723-2733
-
-
Mahnke, K.1
Schönfeld, K.2
Fondel, S.3
-
34
-
-
0037350545
-
Immunotherapy: Past, present and future
-
Waldmann TA. Immunotherapy: past, present and future. Nat. Med. 9, 269-277 (2003).
-
(2003)
Nat. Med
, vol.9
, pp. 269-277
-
-
Waldmann, T.A.1
-
35
-
-
84858416256
-
Antibody-based immunotherapy of cancer
-
Weiner L, Murray J, Shuptrine C. Antibody-based immunotherapy of cancer. Cell 148, 1081-1084 (2012).
-
(2012)
Cell
, vol.148
, pp. 1081-1084
-
-
Weiner, L.1
Murray, J.2
Shuptrine, C.3
-
36
-
-
80054092984
-
Antibody-radionuclide conjugates for cancer therapy: Historical considerations and new trends
-
Steiner M, Neri D. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin. Cancer Res. 17, 6406-6416 (2011).
-
(2011)
Clin. Cancer Res
, vol.17
, pp. 6406-6416
-
-
Steiner, M.1
Neri, D.2
-
37
-
-
0034614897
-
Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
-
Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191, 423-434 (2000).
-
(2000)
J. Exp. Med
, vol.191
, pp. 423-434
-
-
Sauter, B.1
Albert, M.L.2
Francisco, L.3
Larsson, M.4
Somersan, S.5
Bhardwaj, N.6
-
38
-
-
0037033448
-
Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells
-
Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 195, 125-133 (2002).
-
(2002)
J. Exp. Med
, vol.195
, pp. 125-133
-
-
Dhodapkar, K.M.1
Krasovsky, J.2
Williamson, B.3
Dhodapkar, M.V.4
-
39
-
-
65549085367
-
Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: Support for a "vaccinal effect" Of rituximab
-
Hilchey SP, Hyrien O, Mosmann TR et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood 113, 3809-3812 (2009).
-
(2009)
Blood
, vol.113
, pp. 3809-3812
-
-
Hilchey, S.P.1
Hyrien, O.2
Mosmann, T.R.3
-
41
-
-
33749319703
-
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
-
Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006).
-
(2006)
Science
, vol.313
, pp. 1960-1964
-
-
Galon, J.1
Costes, A.2
Sanchez-Cabo, F.3
-
42
-
-
29144514645
-
Effector memory T cells, early metastasis, and survival in colorectal cancer
-
Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353, 2654-2666 (2005).
-
(2005)
N. Engl. J. Med
, vol.353
, pp. 2654-2666
-
-
Pages, F.1
Berger, A.2
Camus, M.3
-
43
-
-
79952093380
-
Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction
-
Mlecnik B, Tosolini M, Kirilovsky A et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J. Clin. Oncol. 29, 610-618 (2011).
-
(2011)
J. Clin. Oncol
, vol.29
, pp. 610-618
-
-
Mlecnik, B.1
Tosolini, M.2
Kirilovsky, A.3
-
44
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
-
(2010)
N. Engl. J. Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
-
45
-
-
79957831345
-
Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma
-
Schwartzentruber DJ, Lawson DH, Richards JM et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364, 2119-2127 (2011).
-
(2011)
N. Engl. J. Med
, vol.364
, pp. 2119-2127
-
-
Schwartzentruber, D.J.1
Lawson, D.H.2
Richards, J.M.3
-
46
-
-
84880745167
-
Prediction of response to anticancer immunotherapy using gene signatures
-
Wang E, Bedognetti D, Marincola FM. Prediction of response to anticancer immunotherapy using gene signatures. J. Clin. Oncol. 31, 2369-2371 (2013).
-
(2013)
J. Clin. Oncol
, vol.31
, pp. 2369-2371
-
-
Wang, E.1
Bedognetti, D.2
Marincola, F.M.3
-
47
-
-
84880730418
-
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: Results of a randomized Phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
-
Kruit WHJ, Suciu S, Dreno B et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized Phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J. Clin. Oncol. 31, 2413-2420 (2013).
-
(2013)
J. Clin. Oncol
, vol.31
, pp. 2413-2420
-
-
Whj, K.1
Suciu, S.2
Dreno, B.3
-
48
-
-
84880755387
-
Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: Phase II randomized study results
-
Vansteenkiste J, Zielinski M, Linder A et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: Phase II randomized study results. J. Clin. Oncol. 31, 2396-2403 (2013).
-
(2013)
J. Clin. Oncol
, vol.31
, pp. 2396-2403
-
-
Vansteenkiste, J.1
Zielinski, M.2
Linder, A.3
-
49
-
-
84880720167
-
Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy
-
Ulloa-Montoya F, Louahed J, Dizier B et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J. Clin. Oncol. 31, 2388-2395 (2013).
-
(2013)
J. Clin. Oncol
, vol.31
, pp. 2388-2395
-
-
Ulloa-Montoya, F.1
Louahed, J.2
Dizier, B.3
-
50
-
-
77954899030
-
Phase i study of single-Agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates
-
Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-Agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167-3175 (2010).
-
(2010)
J. Clin. Oncol
, vol.28
, pp. 3167-3175
-
-
Brahmer, J.R.1
Drake, C.G.2
Wollner, I.3
-
51
-
-
79953154967
-
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans
-
Beatty GL, Chiorean EG, Fishman MP et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612-1616 (2011).
-
(2011)
Science
, vol.331
, pp. 1612-1616
-
-
Beatty, G.L.1
Chiorean, E.G.2
Fishman, M.P.3
-
53
-
-
84879777241
-
Nivolumab plus ipilimumab in advanced melanoma
-
Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
-
(2013)
N. Engl. J. Med
, vol.369
, pp. 122-133
-
-
Wolchok, J.D.1
Kluger, H.2
Callahan, M.K.3
-
54
-
-
84885659813
-
Prostate cancer vaccines: Update on clinical development
-
Geary SM, Salem AK. Prostate cancer vaccines: update on clinical development. Oncoimmunology 2(5) e24523 (2013).
-
(2013)
Oncoimmunology
, vol.2
, Issue.5
-
-
Geary, S.M.1
Salem, A.K.2
-
55
-
-
84865408266
-
Prostate cancer vaccines in clinical trials
-
Lubaroff DM. Prostate cancer vaccines in clinical trials. Expert Rev. Vaccines 11, 857-868 (2012).
-
(2012)
Expert Rev. Vaccines
, vol.11
, pp. 857-868
-
-
Lubaroff, D.M.1
-
56
-
-
84861988397
-
Development of sipuleucel-T: Autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer
-
Sims RB. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Vaccine 30, 4394-4397 (2012).
-
(2012)
Vaccine
, vol.30
, pp. 4394-4397
-
-
Sims, R.B.1
-
57
-
-
0035522738
-
Dendritic cell-based treatment of cancer: Closing in on a cellular therapy
-
Valone FH, Small E, MacKenzie M, et al. Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Cancer J. 7(Suppl. 2), S53-S61 (2001).
-
(2001)
Cancer J
, vol.7 SUPPL. 2
-
-
Valone, F.H.1
Small, E.2
Mackenzie, M.3
-
58
-
-
84862769116
-
An immune-Active tumor microenvironment favors clinical response to ipilimumab
-
Ji RR, Chasalow S, Wang L et al. An immune-Active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 61, 1019-1031 (2012).
-
(2012)
Cancer Immunol. Immunother
, vol.61
, pp. 1019-1031
-
-
Ji, R.R.1
Chasalow, S.2
Wang, L.3
-
59
-
-
82155168544
-
A prospective Phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
-
Hamid O, Schmidt H, Nissan A et al. A prospective Phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J. Transl. Med. 9, 204 (2011).
-
(2011)
J. Transl. Med
, vol.9
, Issue.204
-
-
Hamid, O.1
Schmidt, H.2
Nissan, A.3
-
60
-
-
84655167968
-
Programmed cell removal: A new obstacle in the road to developing cancer
-
Chao MP, Majeti R, Weissman IL. Programmed cell removal: a new obstacle in the road to developing cancer. Nat. Rev. Cancer 12, 58-67 (2012).
-
(2012)
Nat. Rev. Cancer
, vol.12
, pp. 58-67
-
-
Chao, M.P.1
Majeti, R.2
Weissman, I.L.3
-
61
-
-
67650632683
-
CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells
-
Majeti R, Chao MP, Alizadeh AA et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286-299 (2009).
-
(2009)
Cell
, vol.138
, pp. 286-299
-
-
Majeti, R.1
Chao, M.P.2
Alizadeh, A.A.3
-
62
-
-
77954676136
-
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized Phase II/III trial
-
Heiss MM, Murawa P, Koralewski P et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized Phase II/III trial. Int. J. Cancer 127, 2209- 2221 (2010).
-
(2010)
Int. J. Cancer
, vol.127
, pp. 2209-2221
-
-
Heiss, M.M.1
Murawa, P.2
Koralewski, P.3
-
63
-
-
58149384550
-
Graft-versus-leukemia effects of transplantation and donor lymphocytes
-
Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112, 4371-4383 (2008).
-
(2008)
Blood
, vol.112
, pp. 4371-4383
-
-
Kolb, H.J.1
-
64
-
-
0018764352
-
Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts
-
Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 300, 1068-1073 (1979).
-
(1979)
N. Engl. J. Med
, vol.300
, pp. 1068-1073
-
-
Weiden, P.L.1
Flournoy, N.2
Thomas, E.D.3
-
65
-
-
79960299888
-
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
-
Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550-4557 (2011).
-
(2011)
Clin. Cancer Res
, vol.17
, pp. 4550-4557
-
-
Rosenberg, S.A.1
Yang, J.C.2
Sherry, R.M.3
-
66
-
-
79953033883
-
Establishment and large-scale expansion of minimally cultured 'young' tumor infiltrating lymphocytes for adoptive transfer therapy
-
Itzhaki O, Hovav E, Ziporen Y et al. Establishment and large-scale expansion of minimally cultured 'young' tumor infiltrating lymphocytes for adoptive transfer therapy. J. Immunother. 34, 212-220 (2011).
-
(2011)
J. Immunother
, vol.34
, pp. 212-220
-
-
Itzhaki, O.1
Hovav, E.2
Ziporen, Y.3
-
67
-
-
77951714425
-
Clinical responses in a Phase II study using adoptive transfer of short-Term cultured tumor infiltration lymphocytes in metastatic melanoma patients
-
Besser MJ, Shapira-Frommer R, Treves AJ et al. Clinical responses in a Phase II study using adoptive transfer of short-Term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 16, 2646-2655 (2010).
-
(2010)
Clin. Cancer Res
, vol.16
, pp. 2646-2655
-
-
Besser, M.J.1
Shapira-Frommer, R.2
Treves, A.J.3
-
68
-
-
84886944380
-
Trial watch. Adoptive cell transfer immunotherapy
-
Galluzzi L, Vacchelli E, Eggermont A et al. Trial watch. Adoptive cell transfer immunotherapy. Oncoimmunology 1, 306-315 (2012).
-
(2012)
Oncoimmunology
, vol.1
, pp. 306-315
-
-
Galluzzi, L.1
Vacchelli, E.2
Eggermont, A.3
-
69
-
-
0037365973
-
Phase II trial of autologous tumor vaccination, anti-CD3-Activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer
-
Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG. Phase II trial of autologous tumor vaccination, anti-CD3-Activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J. Clin. Oncol. 21, 884-890 (2003).
-
(2003)
J. Clin. Oncol
, vol.21
, pp. 884-890
-
-
Chang, A.E.1
Li, Q.2
Jiang, G.3
Sayre, D.M.4
Braun, T.M.5
Redman, B.G.6
-
70
-
-
0141456489
-
A Phase i trial of CD3/CD28-Activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma
-
Thompson JA, Figlin RA, Sifri-Steele C, Berenson RJ, Frohlich MW. A Phase I trial of CD3/CD28-Activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 9, 3562-3570 (2003).
-
(2003)
Clin. Cancer Res
, vol.9
, pp. 3562-3570
-
-
Thompson, J.A.1
Figlin, R.A.2
Sifri-Steele, C.3
Berenson, R.J.4
Frohlich, M.W.5
-
71
-
-
78751689288
-
Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy
-
Hinrichs CS, Borman ZA, Gattinoni L et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117, 808-814 (2011).
-
(2011)
Blood
, vol.117
, pp. 808-814
-
-
Hinrichs, C.S.1
Borman, Z.A.2
Gattinoni, L.3
-
72
-
-
0035575701
-
Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity
-
Liu K, Rosenberg SA. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J. Immunol. 167, 6356-6365 (2001).
-
(2001)
J. Immunol
, vol.167
, pp. 6356-6365
-
-
Liu, K.1
Rosenberg, S.A.2
-
73
-
-
20144387943
-
Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: Eradication of autologous mouse prostate cancer
-
Zhang Q, Yang X, Pins M et al. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res. 65, 1761-1769 (2005).
-
(2005)
Cancer Res
, vol.65
, pp. 1761-1769
-
-
Zhang, Q.1
Yang, X.2
Pins, M.3
-
74
-
-
27744450650
-
Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy
-
Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175, 7046-7052 (2005).
-
(2005)
J. Immunol
, vol.175
, pp. 7046-7052
-
-
Zhou, J.1
Shen, X.2
Huang, J.3
Hodes, R.J.4
Rosenberg, S.A.5
Robbins, P.F.6
-
75
-
-
77955177074
-
Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein
-
Kalbasi A, Shrimali RK, Chinnasamy D, Rosenberg SA. Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein. J. Immunother. 33, 672-683 (2010).
-
(2010)
J. Immunother
, vol.33
, pp. 672-683
-
-
Kalbasi, A.1
Shrimali, R.K.2
Chinnasamy, D.3
Rosenberg, S.A.4
-
76
-
-
80455162464
-
Inducible apoptosis as a safety switch for adoptive cell therapy
-
Di Stasi A, Tey SK, Dotti G et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673-1683 (2011).
-
(2011)
N. Engl. J. Med
, vol.365
, pp. 1673-1683
-
-
Di Stasi, A.1
Tey, S.K.2
Dotti, G.3
-
77
-
-
70149114880
-
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
-
Johnson LA, Morgan RA, Dudley ME et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535-546 (2009).
-
(2009)
Blood
, vol.114
, pp. 535-546
-
-
Johnson, L.A.1
Morgan, R.A.2
Dudley, M.E.3
-
78
-
-
0033168142
-
Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-Tumor reactivity
-
Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-Tumor reactivity. J. Immunol. 163, 507-513 (1999).
-
(1999)
J. Immunol
, vol.163
, pp. 507-513
-
-
Clay, T.M.1
Custer, M.C.2
Sachs, J.3
Hwu, P.4
Rosenberg, S.A.5
Nishimura, M.I.6
-
79
-
-
33749624177
-
Cancer regression in patients after transfer of genetically engineered lymphocytes
-
Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129 (2006).
-
(2006)
Science
, vol.314
, pp. 126-129
-
-
Morgan, R.A.1
Dudley, M.E.2
Wunderlich, J.R.3
-
80
-
-
84872577768
-
Genetically engineered T cells for the treatment of cancer
-
Essand M, Loskog ASI. Genetically engineered T cells for the treatment of cancer. J. Intern. Med. 273, 166-181 (2013).
-
(2013)
J. Intern. Med
, vol.273
, pp. 166-181
-
-
Essand, M.1
Asi, L.2
-
81
-
-
84858758766
-
Adoptive immunotherapy for cancer: Harnessing the T cell response
-
Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12, 269-281 (2012).
-
(2012)
Nat. Rev. Immunol
, vol.12
, pp. 269-281
-
-
Restifo, N.P.1
Dudley, M.E.2
Rosenberg, S.A.3
-
82
-
-
79952187823
-
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis
-
Parkhurst MR, Yang JC, Langan RC et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620-626 (2011).
-
(2011)
Mol. Ther
, vol.19
, pp. 620-626
-
-
Parkhurst, M.R.1
Yang, J.C.2
Langan, R.C.3
-
83
-
-
65249101637
-
The promise and potential pitfalls of chimeric antigen receptors
-
Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 21, 215-223 (2009).
-
(2009)
Curr. Opin. Immunol
, vol.21
, pp. 215-223
-
-
Sadelain, M.1
Brentjens, R.2
Riviere, I.3
-
84
-
-
0024834988
-
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-Type specificity
-
Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-Type specificity. Proc. Natl Acad. Sci. USA 86, 10024-10028 (1989).
-
(1989)
Proc. Natl Acad. Sci. USA
, vol.86
, pp. 10024-10028
-
-
Gross, G.1
Waks, T.2
Eshhar, Z.3
-
85
-
-
33646440024
-
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience
-
Lamers CHJ, Sleijfer S, Vulto AG et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20-e22 (2006).
-
(2006)
J. Clin. Oncol
, vol.24
-
-
Chj, L.1
Sleijfer, S.2
Vulto, A.G.3
-
86
-
-
50549096284
-
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
-
Till BG, Jensen MC, Wang J et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112, 2261-2271 (2008).
-
(2008)
Blood
, vol.112
, pp. 2261-2271
-
-
Till, B.G.1
Jensen, M.C.2
Wang, J.3
-
87
-
-
33947265424
-
Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma
-
Park JR, DiGiusto DL, Slovak M et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 15, 825-833 (2007).
-
(2007)
Mol. Ther
, vol.15
, pp. 825-833
-
-
Park, J.R.1
Digiusto, D.L.2
Slovak, M.3
-
88
-
-
33750699642
-
A Phase i study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
-
Kershaw MH, Westwood JA, Parker LL et al. A Phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106-6115 (2006).
-
(2006)
Clin. Cancer Res
, vol.12
, pp. 6106-6115
-
-
Kershaw, M.H.1
Westwood, J.A.2
Parker, L.L.3
-
89
-
-
0347994955
-
Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCRz chain
-
Finney HM, Akbar AN, Lawson ADG. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCRz chain. J. Immunol. 172, 104-113 (2004).
-
(2004)
J. Immunol
, vol.172
, pp. 104-113
-
-
Finney, H.M.1
Akbar, A.N.2
Adg, L.3
-
90
-
-
33750061330
-
Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells
-
Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner MK. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 20, 1819-1828 (2006).
-
(2006)
Leukemia
, vol.20
, pp. 1819-1828
-
-
Loskog, A.1
Giandomenico, V.2
Rossig, C.3
Pule, M.4
Dotti, G.5
Brenner, M.K.6
-
91
-
-
79959914449
-
In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB
-
Song DG, Ye Q, Carpenito C et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 71, 4617-4627 (2011).
-
(2011)
Cancer Res
, vol.71
, pp. 4617-4627
-
-
Song, D.G.1
Ye, Q.2
Carpenito, C.3
-
92
-
-
80051775476
-
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia
-
Kalos M, Levine BL, Porter DL et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3(95) 95ra73 (2011).
-
(2011)
Sci. Transl. Med
, vol.3
, Issue.95
-
-
Kalos, M.1
Levine, B.L.2
Porter, D.L.3
-
93
-
-
80051720194
-
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
-
Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011).
-
(2011)
N. Engl. J. Med
, vol.365
, pp. 725-733
-
-
Porter, D.L.1
Levine, B.L.2
Kalos, M.3
Bagg, A.4
June, C.H.5
-
94
-
-
84876325876
-
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
-
Grupp SA, Kalos M, Barrett D et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518 (2013).
-
(2013)
N. Engl. J. Med
, vol.368
, pp. 1509-1518
-
-
Grupp, S.A.1
Kalos, M.2
Barrett, D.3
-
95
-
-
84863669099
-
T-cell therapy at the threshold
-
June C, Rosenberg SA, Sadelain M, Weber JS. T-cell therapy at the threshold. Nat. Biotech. 30, 611-614 (2012).
-
(2012)
Nat. Biotech
, vol.30
, pp. 611-614
-
-
June, C.1
Rosenberg, S.A.2
Sadelain, M.3
Weber, J.S.4
-
96
-
-
84866735170
-
Paths to stemness: Building the ultimate antitumour T cell
-
Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Nat. Rev. Cancer 12, 671-684 (2012).
-
(2012)
Nat. Rev. Cancer
, vol.12
, pp. 671-684
-
-
Gattinoni, L.1
Klebanoff, C.A.2
Restifo, N.P.3
-
97
-
-
79960975784
-
Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression
-
Li Q, Lao X, Pan Q et al. Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin. Cancer Res. 17, 4987-4995 (2011).
-
(2011)
Clin. Cancer Res
, vol.17
, pp. 4987-4995
-
-
Li, Q.1
Lao, X.2
Pan, Q.3
-
98
-
-
0015897005
-
Evaluation of cell-mediated cytotoxic reactivity against tumor associated antigens with 125I-iododeoxyuridine labeled target cells
-
Oldham RK, Herberman RB. Evaluation of cell-mediated cytotoxic reactivity against tumor associated antigens with 125I-iododeoxyuridine labeled target cells. J. Immunol. 111, 862-871 (1973).
-
(1973)
J. Immunol
, vol.111
, pp. 862-871
-
-
Oldham, R.K.1
Herberman, R.B.2
-
99
-
-
0016746934
-
Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells
-
Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int. J. Cancer 16, 230-239 (1975).
-
(1975)
Int. J. Cancer
, vol.16
, pp. 230-239
-
-
Herberman, R.B.1
Nunn, M.E.2
Holden, H.T.3
Lavrin, D.H.4
-
100
-
-
0016762220
-
Natural' killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype
-
Kiessling R, Klein E, Wigzell H. 'Natural' killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur. J. Immunol. 5, 112-117 (1975).
-
(1975)
Eur. J. Immunol
, vol.5
, pp. 112-117
-
-
Kiessling, R.1
Klein, E.2
Wigzell, H.3
-
101
-
-
69049110783
-
Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells
-
Dong Z, Cruz-Munoz ME, Zhong MC, Chen R, Latour S, Veillette A. Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells. Nat. Immunol. 10, 973-980 (2009).
-
(2009)
Nat. Immunol
, vol.10
, pp. 973-980
-
-
Dong, Z.1
Cruz-Munoz, M.E.2
Zhong, M.C.3
Chen, R.4
Latour, S.5
Veillette, A.6
-
102
-
-
0037086131
-
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
-
Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097-2100 (2002).
-
(2002)
Science
, vol.295
, pp. 2097-2100
-
-
Ruggeri, L.1
Capanni, M.2
Urbani, E.3
-
103
-
-
0032558759
-
Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
-
Aversa F, Tabilio A, Velardi A et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N. Engl. J. Med. 339, 1186-1193 (1998).
-
(1998)
N. Engl. J. Med
, vol.339
, pp. 1186-1193
-
-
Aversa, F.1
Tabilio, A.2
Velardi, A.3
-
104
-
-
20144388509
-
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
-
Miller JS, Soignier Y, Panoskaltsis-Mortari A et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105, 3051-3057 (2005).
-
(2005)
Blood
, vol.105
, pp. 3051-3057
-
-
Miller, J.S.1
Soignier, Y.2
Panoskaltsis-Mortari, A.3
-
105
-
-
80053208226
-
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
-
Curti A, Ruggeri L, D'Addio A et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 118, 3273-3279 (2011).
-
(2011)
Blood
, vol.118
, pp. 3273-3279
-
-
Curti, A.1
Ruggeri, L.2
D'Addio, A.3
-
106
-
-
80053465574
-
Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression
-
Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin. Cancer Res. 17, 6287-6297 (2011).
-
(2011)
Clin. Cancer Res
, vol.17
, pp. 6287-6297
-
-
Parkhurst, M.R.1
Riley, J.P.2
Dudley, M.E.3
Rosenberg, S.A.4
-
108
-
-
32944468708
-
Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer
-
Antonia SJ, Mirza N, Fricke I et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res. 12, 878-887 (2006).
-
(2006)
Clin. Cancer Res
, vol.12
, pp. 878-887
-
-
Antonia, S.J.1
Mirza, N.2
Fricke, I.3
-
109
-
-
33749005382
-
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma
-
Inoges S, Rodriguez-Calvillo M, Zabalegui N et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J. Natl Cancer Inst. 98, 1292-1301 (2006).
-
(2006)
J. Natl Cancer Inst
, vol.98
, pp. 1292-1301
-
-
Inoges, S.1
Rodriguez-Calvillo, M.2
Zabalegui, N.3
-
110
-
-
24944478531
-
Leveraging the activity of tumor vaccines with cytotoxic chemotherapy
-
Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. 65, 8059-8064 (2005).
-
(2005)
Cancer Res
, vol.65
, pp. 8059-8064
-
-
Emens, L.A.1
Jaffee, E.M.2
-
111
-
-
84885643372
-
Oncolytic viruses: Do they have a role in anti-cancer therapy?
-
Prestwich RJ, Errington F, Harrington KJ, Pandha HS, Selby P, Melcher A. Oncolytic viruses: do they have a role in anti-cancer therapy? Clin. Med. Oncol. 2, 83-96 (2008).
-
(2008)
Clin. Med. Oncol
, vol.2
, pp. 83-96
-
-
Prestwich, R.J.1
Errington, F.2
Harrington, K.J.3
Pandha, H.S.4
Selby, P.5
Melcher, A.6
-
112
-
-
84863547754
-
Oncolytic viruses for induction of anti-Tumor immunity
-
Tong AW, Senzer N, Cerullo V, Templeton NS, Hemminki A, Nemunaitis J. Oncolytic viruses for induction of anti-Tumor immunity. Curr. Pharm. Biotechnol. 13, 1750-1760 (2012).
-
(2012)
Curr. Pharm. Biotechnol
, vol.13
, pp. 1750-1760
-
-
Tong, A.W.1
Senzer, N.2
Cerullo, V.3
Templeton, N.S.4
Hemminki, A.5
Nemunaitis, J.6
-
113
-
-
83355163508
-
Oncolytic herpes virus induces effective anti-cancer immunity against murine colon cancer
-
Shirota T, Kasuya H, Kodera Y et al. Oncolytic herpes virus induces effective anti-cancer immunity against murine colon cancer. Hepatogastroenterology 58, 1482-1489 (2011).
-
(2011)
Hepatogastroenterology
, vol.58
, pp. 1482-1489
-
-
Shirota, T.1
Kasuya, H.2
Kodera, Y.3
-
114
-
-
79957902460
-
Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: Preclinical and clinical demonstration of combination efficacy
-
Heo J, Breitbach CJ, Moon A et al. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol. Ther. 19, 1170-1179 (2011).
-
(2011)
Mol. Ther
, vol.19
, pp. 1170-1179
-
-
Heo, J.1
Breitbach, C.J.2
Moon, A.3
-
115
-
-
84858702868
-
Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-Tumor immunity
-
Stephenson KB, Barra NG, Davies E, Ashkar AA, Lichty BD. Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-Tumor immunity. Cancer Gene Ther. 19, 238-246 (2012).
-
(2012)
Cancer Gene Ther
, vol.19
, pp. 238-246
-
-
Stephenson, K.B.1
Barra, N.G.2
Davies, E.3
Ashkar, A.A.4
Lichty, B.D.5
-
116
-
-
84869217555
-
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer
-
Hastie E, Grdzelishvili VZ. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J. General Virol. 93, 2529-2545 (2012).
-
(2012)
J. General Virol
, vol.93
, pp. 2529-2545
-
-
Hastie, E.1
Grdzelishvili, V.Z.2
-
117
-
-
84871025600
-
Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: Implication of leucocyte recruitment
-
Dempe S, Lavie M, Struyf S et al. Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment. Cancer Immunol. Immunother. 61, 2113-2123 (2012).
-
(2012)
Cancer Immunol. Immunother
, vol.61
, pp. 2113-2123
-
-
Dempe, S.1
Lavie, M.2
Struyf, S.3
|